Replimune/REPL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Replimune

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

Ticker

REPL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Philip Astley-Sparke

Employees

331

Headquarters

Woburn, United States

Replimune Metrics

BasicAdvanced
$324M
Market cap
-
P/E ratio
-$3.24
EPS
1.16
Beta
-
Dividend rate
$324M
1.15704
$24.81
$4.92
909K
10.724
18.216
18.941
-38.05%
-46.42%
-40.71%
0.864
0.864
-8.10%

What the Analysts think about Replimune

Analyst Ratings

Majority rating from 9 analysts.
Buy

Replimune Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$0
NaN%
Net income
-$55M
7.63%
Profit margin
0.00%
NaN%

Replimune Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.47%
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.75
-$0.90
-$0.77
-$0.82
-
Expected
-$0.84
-$0.86
-$0.93
-$0.79
-$0.87
Surprise
-11.14%
5.18%
-16.99%
3.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Replimune stock?

Replimune (REPL) has a market cap of $324M as of June 15, 2024.

What is the P/E ratio for Replimune stock?

The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of June 15, 2024.

Does Replimune stock pay dividends?

No, Replimune (REPL) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Replimune dividend payment date?

Replimune (REPL) stock does not pay dividends to its shareholders.

What is the beta indicator for Replimune?

Replimune (REPL) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Replimune stock price target?

The target price for Replimune (REPL) stock is $13.56, which is NaN% below the current price of $. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Replimune stock

Buy or sell Replimune stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing